Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance, Ipsogen to Co-market Their Flagship Products in New Pharmacogenomic Alliance

NEW YORK, Nov. 16 (GenomeWeb News) - Genaissance Pharmaceuticals and Ipsogen will co-market their flagship technologies to offer gene-expression and genotyping technologies to cancer-based drug makers, the firms said today.

 

Specifically, the collaboration will jointly market Genaissance's haplotyping and high-throughout genotyping technologies, and Ipsogen's Oncogenomic platform, used for gene-expression profiling.

 

Financial terms were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.